For US Healthcare Professionals Only
Filter
Effect of zilucoplan stratified by age of myasthenia gravis onset: RAISE-XT 120-week post hoc analysis
Efficacy of long-term rozanolixizumab treatment cycles in patients with generalized myasthenia gravis: A subgroup analysis of Phase 3 studies
Beyond income, education and insurance coverage: The utility of CORE-5 social risk screening in neuromuscular practice for Black patients with generalized myasthenia gravis
Living with ocular symptoms of myasthenia gravis and patient priorities for clinical trials
Individual item-level analyses of myasthenia gravis-specific outcomes during zilucoplan treatment in RAISE and RAISE-XT
Minimal symptom expression in myasthenia gravis: A post hoc analysis of Phase 3 rozanolixizumab studies
Rozanolixizumab for ocular myasthenia gravis: Study design of a Phase 3, randomized, double-blind, placebo-controlled trial (MyVision) and open-label extension study (MyVisionXT)
Effect of rozanolixizumab on MG-ADL and QMG items: A post hoc Phase 3 final pooled analysis
Clinical determinants of new rozanolixizumab treatment cycles in patients with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG and open-label extension studies
Vitaccess Real Myasthenia Gravis studies protocol: Registry-based mixed-methods studies on treatment outcomes in patients initiated on zilucoplan or rozanolixizumab in the real world
Effect of rozanolixizumab on ocular symptoms in generalized myasthenia gravis: Analysis of Phase 3 studies
Characterization of patients with generalized myasthenia gravis on zilucoplan treatment in European Managed Access Programmes
Improvements in Myasthenia Gravis Symptoms Patient-Reported Outcomes during long-term cyclic rozanolixizumab treatment
Initiating rozanolixizumab in the United States: Treatment utilization among patients with myasthenia gravis
Achievement of minimal symptom expression in patients with generalized myasthenia gravis receiving zilucoplan: A 120-week post hoc analysis of RAISE-XT
Quality of life in myasthenia gravis: Post hoc pooled analysis of Phase 3 rozanolixizumab studies
Healthcare provider perspectives on barriers and challenges to equitable care among patient subpopulations with generalized myasthenia gravis: A US national survey
Switching to rozanolixizumab from efgartigimod: Real-world outcomes in patients with myasthenia gravis in the United States
Characterization of patients with generalized myasthenia gravis on rozanolixizumab treatment in European Managed Access Programmes
Repeated cycles of rozanolixizumab treatment in anti‑muscle‑specific tyrosine kinase antibody‑positive generalized myasthenia gravis
Rozanolixizumab is not detectable in breast milk after a single dose in healthy, lactating women: Results from an open-label, Phase 1 study